Meta Pixel

News and Announcements

Debunking the Top 3 Myths About Raising Capital

  • Published August 31, 2023 1:19AM UTC
  • Publisher Wholesale Investor
  • Categories Capital Raising Tips

Raising capital is a journey filled with challenges and opportunities. As a founder, director, or CEO, understanding the process is crucial to successfully navigate this journey. Today, let’s debunk three common myths about raising capital and provide valuable insights based on real-world experiences.

YouTube player

Myth 1: Raising Capital Only Takes 2-3 Months

The first myth is that raising capital only takes two to three months. In reality, it can take anywhere from six months to 18 months. Capital raising takes time and often involves a significant amount of behind-the-scenes work. It’s not uncommon for companies to work on a capital raise for up to a year before closing the deal.

Myth 2: Advisors Use Sophisticated Analytical Tools

The second myth is that corporate advisors and investment banks use sophisticated analytical tools for their transactions. However, many companies and advisors use simple tools like Excel spreadsheets and emails for their transactions. The use of analytics in the capital raising process is crucial, and companies should have visibility over who is involved and what is happening inside the deal room.

Myth 3: VCs are the Main Investors

The third myth is that venture capitalists (VCs) are the main investors in this space. While VCs play a significant role, they are not the only investors. High net worth family offices and industry participants are often the main investors in this space. There are many different investment groups that operate outside of the VC structure.

In conclusion, raising capital is a journey that involves different stages, each with its own set of challenges. Understanding these stages can help you better navigate the capital raising process and increase your chances of success. Remember, every stage of your business, from ideation to pre-IPO, presents unique opportunities to attract investment and drive growth. Embrace these challenges, learn from them, and keep moving forward on your capital raising journey.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now